# A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

> **NCT02544763** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 224 (actual)

## Conditions studied

- Tuberous Sclerosis Complex
- Seizures

## Interventions

- **DRUG:** GWP42003-P
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02544763
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-06
- **Primary completion:** 2019-01-22
- **Final completion:** 2019-02-26
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544763, "A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02544763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*